JP2023512707A - Ｒｎａ負荷ナノ粒子およびがんの治療のためのそれらの使用 - Google Patents

Ｒｎａ負荷ナノ粒子およびがんの治療のためのそれらの使用 Download PDF

Info

Publication number
JP2023512707A
JP2023512707A JP2022547802A JP2022547802A JP2023512707A JP 2023512707 A JP2023512707 A JP 2023512707A JP 2022547802 A JP2022547802 A JP 2022547802A JP 2022547802 A JP2022547802 A JP 2022547802A JP 2023512707 A JP2023512707 A JP 2023512707A
Authority
JP
Japan
Prior art keywords
rna
tumor
nucleic acid
cells
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022547802A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021158996A5 (https=
JP2023512707A5 (https=
Inventor
セイヤー、エリアス
メンデス－ゴメス、ヘクター、ルーベン
クダイサット、サディーム
デリーロール、ロイク、ピエール
ミッチェル、デュエイン
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド filed Critical ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Publication of JP2023512707A publication Critical patent/JP2023512707A/ja
Publication of JPWO2021158996A5 publication Critical patent/JPWO2021158996A5/ja
Publication of JP2023512707A5 publication Critical patent/JP2023512707A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022547802A 2020-02-05 2021-02-05 Ｒｎａ負荷ナノ粒子およびがんの治療のためのそれらの使用 Pending JP2023512707A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062970646P 2020-02-05 2020-02-05
US62/970,646 2020-02-05
US202062991404P 2020-03-18 2020-03-18
US62/991,404 2020-03-18
PCT/US2021/016925 WO2021158996A1 (en) 2020-02-05 2021-02-05 Rna-loaded nanoparticles and use thereof for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2023512707A true JP2023512707A (ja) 2023-03-28
JPWO2021158996A5 JPWO2021158996A5 (https=) 2024-02-13
JP2023512707A5 JP2023512707A5 (https=) 2024-02-13

Family

ID=77200411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022547802A Pending JP2023512707A (ja) 2020-02-05 2021-02-05 Ｒｎａ負荷ナノ粒子およびがんの治療のためのそれらの使用

Country Status (4)

Country Link
US (1) US20230096704A1 (https=)
EP (1) EP4099988A4 (https=)
JP (1) JP2023512707A (https=)
WO (1) WO2021158996A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3999034A4 (en) * 2019-07-19 2023-08-23 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticles
JP2024517287A (ja) 2021-05-07 2024-04-19 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ｃａｒ ｔ細胞療法の方法
CN113876691B (zh) * 2021-09-26 2023-08-08 华中科技大学同济医学院附属协和医院 一种包载靶标lncRNA Pvt1纳米粒子的水凝胶及其制备方法和应用
WO2023196232A1 (en) * 2022-04-04 2023-10-12 University Of Florida Research Foundation, Inc. Method of characterizing tumors
WO2025207807A1 (en) * 2024-03-27 2025-10-02 The University Of Florida Research Foundation, Inc. Ctc rna-loaded nanoparticles and use thereof for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514076A (ja) * 2012-03-26 2015-05-18 バイオンテック アーゲー 免疫療法のためのｒｎａ製剤
JP2017500312A (ja) * 2013-12-13 2017-01-05 ナンヤン テクノロジカル ユニヴァーシティー 多層ナノ粒子並びにその製造方法及び使用方法
WO2018144082A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Rna cancer vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
IN190388B (https=) * 1997-10-01 2003-07-26 Biomira Usa Inc
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
CN111630173A (zh) * 2017-10-19 2020-09-04 库瑞瓦格股份公司 新型人工核酸分子
CA3099519A1 (en) * 2018-05-08 2019-11-14 University Of Florida Research Foundation, Incorporated Magnetic liposomes and related treatment and imaging methods
EP3942050A4 (en) * 2019-03-19 2023-02-22 Arcturus Therapeutics, Inc. PROCEDURE FOR THE PRODUCTION OF LIPID-COATED RNA NANOPARTICLES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514076A (ja) * 2012-03-26 2015-05-18 バイオンテック アーゲー 免疫療法のためのｒｎａ製剤
JP2017500312A (ja) * 2013-12-13 2017-01-05 ナンヤン テクノロジカル ユニヴァーシティー 多層ナノ粒子並びにその製造方法及び使用方法
WO2018144082A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Rna cancer vaccines

Also Published As

Publication number Publication date
US20230096704A1 (en) 2023-03-30
EP4099988A4 (en) 2024-03-13
WO2021158996A1 (en) 2021-08-12
EP4099988A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
Mendez-Gomez et al. RNA aggregates harness the danger response for potent cancer immunotherapy
JP2023512707A (ja) Ｒｎａ負荷ナノ粒子およびがんの治療のためのそれらの使用
US12514930B2 (en) Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
US20230226169A1 (en) Multilamellar rna nanoparticle vaccine against sars-cov-2
JP2022519718A (ja) 加齢および加齢性臓器不全に関連する疾患の処置のためのテロメラーゼ含有エキソソーム
US20250345417A1 (en) Compositions and methods for treatment of melanoma
AU2019265707B2 (en) Magnetic liposomes and related treatment and imaging methods
US20230346700A1 (en) Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
JP7783628B2 (ja) 多層ｒｎａナノ粒子
US20240238418A1 (en) Car t cell therapy method
US20250231177A1 (en) Method of characterizing tumors
CA3166934A1 (en) Rna-loaded nanoparticles and use thereof for the treatment of cancer
WO2025207807A1 (en) Ctc rna-loaded nanoparticles and use thereof for the treatment of cancer
Liu Nanoparticle Mediated Chemo-Immunotherapy for Triple Negative Breast Cancer
CN118308350A (zh) cGAS-STING通路激动剂及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127